MarginsXMarginsX
Home › Markets › Health Care › PEPG

PepGen Inc. (PEPG)

PEPG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.19
-3.90% on the day
Market cap
$395.0M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerPEPG on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001835597
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
4.2 months
$22.0M cash at September 30, 2026
Share count, 1 year
+0.7%
2025-11-05 to 2026-11-04 · +190.8% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$59K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$22.0M cash; operating cash flow -$15.8M a quarter.Report 2026-09-30
Shares outstanding69,261,282 (2026-11-04); 68,748,224 a year earlier; 23,813,547 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $59K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$19.4M-$13.2M$22.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$17.8M-$15.8M$22.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$17.8M-$18.4M$42.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$18.3M-$15.8M$60.5MNo debt tagsNeeds four quarters10-K 2026-03-04
Q3 2025
2025-09-30
Not filed-$18.0M-$19.3M$142.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$23.1M-$23.6M$35.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$30.2M-$22.9M$43.6MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$22.2M-$19.5M$49.4MNo debt tagsNeeds four quarters10-K 2026-03-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-12
Latest annual report10-K2026-03-04
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 309 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+76.5%
1 month+74.4%
3 months+46.3%
Year to date-33.0%
1 year-10.8%
From 52-week high-39.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
CRMDCorMedix Inc.$4.82+3.43%$383.4M
PRTAProthena Corporation plc$7.97-2.33%$409.3M
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier